Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation

Transplantation Proceedings

Volumn 31, Issue 1-2 SUPPL., 1999, Pages 1140-1141

  Keown, P ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

CLINICAL PROTOCOL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; GRAFT SURVIVAL; HEALTH STATUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; QUESTIONNAIRES;

EID: 0033062494     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0041-1345(98)02103-4     Document Type: Article

References (9)

1. Detsky AS, Naglie IG: Ann Int Med 113:147, 1990
2. Keown PA: Transplant Proc (in press)
3. UK Registry
4. Ferguson B, Keown PA: Infect Control Hosp Epidemiol 16:240, 1995
5. Laupacis A, Keown P, Pus N, et al: Kidney Int 50:235, 1996
6. Evans RW, Kitzmann DJ: Surg Clin North Am 78:149, 1998
7. Keown PA, Landsberg D, Lawen J, et al: Transplant Proc 27:1845, 1995
8. Sullivan SD, Garrison LP, Best JH, et al: J Am Soc Nephrol 1592, 1997
9. Sharples LD, Briggs A, Caine N, et al: Transplantation 62:615, 1996